

CLAIM LISTING

Claims 1 to 28 (canceled).

29. (currently amended) A method for treating the lower urinary tract symptoms associated with benign prostate hyperplasia in mammals comprising administering to a mammal ~~in need thereof~~ suffering from benign prostate hyperplasia an effective amount of an alpha-adrenoreceptor antagonist in combination with a muscarinic antagonist.

30. (currently amended) The method of claim 29 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist ~~is~~ are administered simultaneously.

31. (currently amended) The method of claim 29 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist ~~is~~ are administered separately.

32. (currently amended) The method of claim 29 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist ~~is~~ are administered sequentially.

33. (previously presented) The method of claim 29 wherein the alpha-adrenoceptor antagonist is non-selective or selective for α_1 receptors.

34. (previously presented) The method of claim 29 wherein said alpha-adrenoceptor antagonist is selected from the group consisting of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, doxazosin, tetrazosin, abanoquil, prazosin, and indoramin or pharmaceutically acceptable salts thereof.

35. (previously presented) The method of claim 29 wherein said muscarinic antagonist is non-selective or selective for M_3 receptors.

36. (previously presented) The method of claim 29 wherein said muscarinic antagonist is selected from the group consisting of darifenacin, tolterodine and oxybutynin or pharmaceutically acceptable salts thereof.

37. (previously presented) The method of claim 29 wherein said muscarinic antagonist is darifenacin, or a pharmaceutically acceptable salt thereof.

38. (previously presented) The method of claim 29 wherein said alpha-adrenoreceptor antagonist is doxazosin and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.

39. (previously presented) The method of claim 29 wherein said alpha-adrenoceptor antagonist is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.